Mesoblast (ASX:MSB): How Has Its FDA Approval Influenced Analyst Views?

Sonal Goyal

08 October 2026 05:25 AM AEDT

Mesoblast (ASX:MSB): How Has Its FDA Approval Influenced Analyst Views?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Consensus rating of Buy from 6 analysts: 6 Buy or equivalent, 0 Hold, 0 Sell or equivalent.
Mean price target of A$3.64 against a share price of A$1.94 on 8 October 2026, an implied upside of 87.9%.
Analyst targets range from A$2.90 to A$4.45.
Mesoblast (ASX:MSB; Nasdaq:MESO) announced on 23 September 2026 in Melbourne (24 September in New York) that it has received approval from the US Food and Drug Administration to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of Ryoncil (remestemcel-L-rknd).

Mesoblast (ASX:MSB) carries a consensus analyst rating of Buy. Of the 6 analyst recommendations recorded, 6 are Buy or equivalent, 0 are Hold and 0 are Sell or equivalent. The mean price target is A$3.64, with targets ranging from A$2.90 to A$4.45, against a current share price of A$1.94 (8 October 2026). Mesoblast Limited is a developer of allogeneic cellular medicines for inflammatory diseases, listed on the ASX and the Nasdaq.

Company name	Mesoblast
Ticker	(ASX:MSB)
Exchange	ASX (Australian Securities Exchange)
Current share price	A$1.94
Price date	8 October 2026
Number of analysts	6
Rating consensus	Buy
Consensus price target (mean)	A$3.64
Highest target	A$4.45
Lowest target	A$2.90
Implied upside/downside to mean target	Implied upside of 87.9%

Latest developments

Mesoblast (ASX:MSB; Nasdaq:MESO) announced on 23 September 2026 in Melbourne (24 September in New York) that it has received approval from the US Food and Drug Administration to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of Ryoncil (remestemcel-L-rknd).

The company said the assay will ensure sufficient sensitivity to detect shifts in potency that could arise during changes to Manufacturing processes or production in new facilities. It will be used as part of a matrix to release each commercial batch of Ryoncil, together with existing potency assays measuring IL-2Rα inhibition and Cell Adhesion and Proliferation, as set out in the product's Biologics License.

Ryoncil is described as the first industrially manufactured allogeneic mesenchymal stromal cell (MSC) product approved by the FDA for any indication, and the only MSC product approved for patients aged two months or older with steroid-refractory acute graft versus host disease. Mesoblast said it and the FDA have worked closely since commercial approval to align on advancements to manufacturing processes and quality control assays.

Risks and what to watch

The announcement concerns a quality control assay and does not give sales, Revenue or timing information for Ryoncil. The company notes the assay supports changes in manufacturing processes or new facilities, but does not describe any such change. Cell therapy products depend on regulatory compliance, manufacturing consistency and market adoption, and additional indications are in development.

Next milestones

Items to watch include implementation of the TIBA assay in commercial batch release, any manufacturing process or Facility changes referenced by the company, and updates on Ryoncil commercial performance and additional indications for the remestemcel-L and rexlemestrocel-L platforms.

FAQs

Q: What is the consensus analyst rating for Mesoblast (ASX:MSB)?

A:The consensus rating is Buy, based on 6 analyst recommendations: 6 Buy or equivalent, 0 Hold and 0 Sell or equivalent.

Q: What are the analyst price targets for Mesoblast (ASX:MSB)?

A:The mean price target is A$3.64, with a highest target of A$4.45 and a lowest target of A$2.90. The share price on 8 October 2026 was A$1.94.

Q: What did Mesoblast (ASX:MSB) announce on 23 September 2026?

A:Mesoblast announced FDA approval of a new potency assay, TIBA, to release and monitor all new commercial lots of Ryoncil, used alongside existing potency assays.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.